IP Library › Granted Patent US 12703852
Granted Patent B2
US 12703852 · App. 16/607,967 · Granted Aug 11, 2026

Hematopoietic progenitor cell marker

Inventors: Shin Kaneko (Kyoto, JP); Shoichi Iriguchi (Kyoto, JP); Yuta Mishima (Kyoto, JP); Yoshiaki Kassai (Kanagawa, JP); Akira Hayashi (Kanagawa, JP); Suguru Arima (Kanagawa, JP)
Assignees: KYOTO UNIVERSITY; TAKEDA PHARMACEUTICAL COMPANY LIMITED
C12N5/0638C12N5/0636C12N5/0696G01N33/56966C12N2501/505C12N2506/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703852
App. No.
16/607,967
Granted
Aug 11, 2026
Kind
B2
Abstract

Provided is a method for producing a CD4/CD8 double positive cell, including the following steps: step 1: separating, from a cell population containing a hematopoietic progenitor cell, a cell expressing one or more kinds of molecules selected from the first group consisting of CD24, CD62L, CD90, CD143, CD263, Notch3, CD32, CD39, CD49a, CD164, CD317, CD200, CD218a, CD7, CD144, CD56, CD226, CD262 and CD325, and/or a cell not expressing one or more kinds of molecules selected from the second group consisting of CD49f, CD51, CD102, CD42b, CD61, CD62P, CD69, CD102 and CD156c, and step 2: differentiating the cell separated in step 1 into a CD4/CD8 double positive cell.

Claims (10)

1 . A method for producing CD4/CD8 double positive cells, the method comprising

(i) inducing differentiation of a population of human induced pluripotent stem cells to obtain a cell population comprising hematopoietic progenitor cells (a) expressing CD34, CD218a and CD43, and (b) not expressing CD235a and CD14,

(ii) isolating hematopoietic progenitor cells expressing CD34, CD218a and CD43, and (ii) not expressing CD235a and CD14 from the cell population comprising hematopoietic progenitor cells obtained from step (i), and

(iii) differentiating the isolated hematopoietic progenitor cells from step (ii) into CD4/CD8 double positive cells.

2 . A method for producing CD8 single positive cells, the method comprising

(i) inducing differentiation of a population of human induced pluripotent stem cells to obtain a cell population comprising hematopoietic progenitor cells (a) expressing CD34, CD218a and CD43, and (b) not expressing CD235a and CD14,

(ii) isolating hematopoietic progenitor cells expressing CD34, CD218a and CD43, and (ii) not expressing CD235a and CD14 from the cell population comprising hematopoietic progenitor cells obtained from step (i), and

(iii) differentiating the isolated hematopoietic progenitor cells from step (ii) into CD4/CD8 double positive cells, and

(iv) inducing the CD4/CD8 double positive cells from step (iii) into single positive CD8 cells.

3 . The method according to claim 2 , wherein said CD8 single positive cells are cytotoxic T lymphocytes.